PepGen Ltd (PEPG) - Net Assets
Based on the latest financial reports, PepGen Ltd (PEPG) has net assets worth $147.44 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($173.91 Million) and total liabilities ($26.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PepGen Ltd (PEPG) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $147.44 Million |
| % of Total Assets | 84.78% |
| Annual Growth Rate | 83.43% |
| 5-Year Change | 10.78% |
| 10-Year Change | N/A |
| Growth Volatility | 460.33 |
PepGen Ltd - Net Assets Trend (2019–2025)
This chart illustrates how PepGen Ltd's net assets have evolved over time, based on quarterly financial data. See PepGen Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for PepGen Ltd (2019–2025)
The table below shows the annual net assets of PepGen Ltd from 2019 to 2025. For live valuation and market cap data, see how much is PepGen Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $147.44 Million | +24.30% |
| 2024-12-31 | $118.62 Million | +9.41% |
| 2023-12-31 | $108.42 Million | -39.64% |
| 2022-12-31 | $179.63 Million | +34.97% |
| 2021-12-31 | $133.09 Million | +1261.71% |
| 2020-12-31 | $9.77 Million | +152.75% |
| 2019-12-31 | $3.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PepGen Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35872400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $11.00K | 0.01% |
| Other Components | $508.54 Million | 344.91% |
| Total Equity | $147.44 Million | 100.00% |
PepGen Ltd Competitors by Market Cap
The table below lists competitors of PepGen Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UNIBEP S.A.
WAR:UNI
|
$121.76 Million |
|
Odlewnie Polskie SA
WAR:ODL
|
$121.76 Million |
|
MSM Malaysia Holdings Bhd
KLSE:5202
|
$121.78 Million |
|
Epileds Technologies Inc
TW:4956
|
$121.79 Million |
|
Moens Bank A/S
CO:MNBA
|
$121.72 Million |
|
Value Valves Co Ltd
TWO:4580
|
$121.65 Million |
|
Easy Field
TWO:6425
|
$121.64 Million |
|
HMA AGRO INDUSTRIES ORD (BSE)
NSE:HMAAGRO
|
$121.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PepGen Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 118,620,000 to 147,444,000, a change of 28,824,000 (24.3%).
- Net loss of 89,655,000 reduced equity.
- New share issuances of 108,100,000 increased equity.
- Other comprehensive income decreased equity by 12,000.
- Other factors increased equity by 10,391,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-89.66 Million | -60.81% |
| Share Issuances | $108.10 Million | +73.32% |
| Other Comprehensive Income | $-12.00K | -0.01% |
| Other Changes | $10.39 Million | +7.05% |
| Total Change | $- | 24.30% |
Book Value vs Market Value Analysis
This analysis compares PepGen Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.51x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 10.37x to 0.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.17 | $1.79 | x |
| 2020-12-31 | $0.44 | $1.79 | x |
| 2021-12-31 | $5.94 | $1.79 | x |
| 2022-12-31 | $11.49 | $1.79 | x |
| 2023-12-31 | $4.56 | $1.79 | x |
| 2024-12-31 | $3.76 | $1.79 | x |
| 2025-12-31 | $3.49 | $1.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PepGen Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -60.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (-60.81%) is below the historical average (-46.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -34.81% | 0.00% | 0.00x | 1.08x | $-1.73 Million |
| 2020 | -19.33% | 0.00% | 0.00x | 1.09x | $-2.87 Million |
| 2021 | -20.50% | 0.00% | 0.00x | 1.08x | $-40.59 Million |
| 2022 | -38.47% | 0.00% | 0.00x | 1.21x | $-87.07 Million |
| 2023 | -72.52% | 0.00% | 0.00x | 1.32x | $-89.47 Million |
| 2024 | -75.86% | 0.00% | 0.00x | 1.27x | $-101.84 Million |
| 2025 | -60.81% | 0.00% | 0.00x | 1.18x | $-104.40 Million |
Industry Comparison
This section compares PepGen Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PepGen Ltd (PEPG) | $147.44 Million | -34.81% | 0.18x | $121.74 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more